Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.
Josh Makower, partner at venture capital investor New Enterprise Associates (NEA), has worked within life sciences for more than 20 years. He has learnt that “IP is a must” in the industry, due to the extensive time and costs involved in bringing a health product to market.
“If we did not believe the idea could be protected, there would be no interest in investing,” he explains.
Makower adds: “IP factors in very heavily when we’re looking at new companies, and the breadth and novelty of an invention as well as whether it can be practised without infringement is a fundamental screen before we’ll get involved.”
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
LSIPR 50 2018, Josh Makower, New Enterprise Associates, investment, medical technology, start-ups, novelty, IP infringement, patient care, medical devices
